世界の視神経炎市場 – 業界動向と2030年までの予測

視神経炎市場の分析と規模

多発性硬化症（MS）患者の約40％から50％が視神経炎を発症し、視神経炎患者の約30％に多発性硬化症の兆候が見られます。2021年にNCBIが発表した最新の研究では、視神経炎のリスクは20歳から40歳の人の方が高いことがわかりました。静脈内投与により、視神経炎治療の世界的な需要が生まれると予想されています。

データブリッジ市場調査は、2023年から2030年の予測期間における視神経炎市場の成長率を分析しています。視神経炎市場の予想CAGRは、上記の予測期間において約5％になる傾向があります。市場は2022年に2億490万米ドルと評価され、2030年までに3億270万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

視神経炎市場の範囲とセグメンテーション

Market Definition

Optic neuritis is a kind of nerve damage that occurs because of high level of blood sugar in the body. The symptoms can initiate from pain, numbness in legs and feet, to urinary tract, blood vessels and heart. It is a type of diabetes complication which may affect people with diabetes. Optic neuritis is a serious and common complication of long term type 1 and type 2 diabetes.

Optic Neuritis Market Dynamics

Drivers

• Rising Demand of Therapy Segment

There are different types of therapy that increases the demand of the market. Steroidal therapy includes corticosteroid drugs, which have proven efficient for many years. This segment is anticipated to show major market share, due to its proven efficacy and increasing availability across the globe. Supplementary therapy, on the other hand, includes vitamin supplementation therapy with vitamin B12. Immunomodulators therapy involves disease modifying agents, such as interferons beta1a and beta1b that are found to be beneficial in the treatment of optic neuritis and multiple sclerosis.

Opportunities

• Growth in Smoking and Lifestyle Changes

Cigarette smoking is one of the top causes of preventable disease and death in the U.S. It  results for more than 480,000 deaths each year. Additionally, the lifestyle changes that are attained by today’s population such as unhealthy lifestyle, poor diet, stress and many such factors altogether contribute to the developing opportunities of the market.

• Increasing Incidence of Optic neuritis

Optic neuritis disease can occur at any age, but many of the cases occur in women who are between the age group of 20 to 40 years. In addition to this, as per the Optic Neuritis Foundation Inc, an estimation of 15-20% of the people suffering from optic neuritis are expected to end up suffering from multiple sclerosis.

Restraints/Challenges

• Increase in stringent regulatory policies

The strict regulatory policies is set to impede the global optic neuritis market growth during the forecast period. The strict regulations, delays in Food and Drug Administration certifications, product recalls, and other similar issues may further impede the growth of this industry.

• High Cost of Treatment

The enormous expenditure which is required for the treatment processes hamper the market growth. Several market players make huge investment in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased. For instance, developing new drug treatments for a disease costs $314 million to $2.8 billion, will impede the market during the forecast period.

This optic neuritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the optic neuritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Optic Neuritis Market Scope

The optic neuritis market is segmented on the basis of type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Oral Corticosteriods
• Intravenous Corticosteriods

Applications

• Paediatric Use
• Geriatric Use

End-User

• Hospitals
• Research Institutes
• Specialty Clinics

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Global Optic Neuritis Market Regional Analysis/Insights

The optic neuritis market is analyzed and market size insights and trends are provided by type, application, distribution channel and end-user as referenced above.

The major countries covered in the optic neuritis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities.

Asia-Pacific is expected to account for the largest market share in the coming years for the optic neuritis market due to increased new research and developments on optic neuritis market.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。   

競争環境と世界の視神経炎市場シェア分析

視神経炎市場の競争環境は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータポイントは、視神経炎市場に関連する会社の焦点にのみ関連しています。

視神経炎市場で活動している主要企業は次のとおりです。

• エアリー・ファーマシューティカルズ社（米国）
• アッヴィ社（米国）
• バウシュ・ヘルス・カンパニーズ（カナダ）
• メルク社（米国）
• ファイザー社（米国）
• テバ製薬工業株式会社（イスラエル）
• アイポイント・ファーマシューティカルズ（米国）
• アモルフェックス・セラピューティクス・ホールディングス（米国）
• クボタビジョン株式会社（米国）
• アルコンビジョンLLC（スイス）
• エレックスメディカル（オーストラリア）
• ルメニス・ビー・リミテッド（イスラエル）
• エイコーンバイオメディカル社（米国）
• アステラス製薬株式会社（日本）
• Glenmark Pharmaceuticals Ltd (インド)
• バイエルAG（ドイツ）
• ノバルティスAG（スイス）

SKU-57350